🇺🇸 FDA
Patent

US 6881420

Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation

expired A61KA61K31/663A61K9/0065

Quick answer

US patent 6881420 (Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Apr 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Apr 19 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/663, A61K9/0065, A61K9/2027, A61K9/205